Article may be outdated

This article is 7 days old. Some details may have changed since publication.

Contagion Live·4 min read·hard

CDC: NDM Drives 92% Rise in Carbapenemase-Producing CRE Among US Children

CDC: NDM Drives 92% Rise in Carbapenemase-Producing CRE Among US Children
✦AI Summary

A new CDC analysis reveals a 92% increase in carbapenemase-producing CRE infections among US children between 2019 and 2024. The rise is primarily driven by the spread of New Delhi metallo-β-lactamase (NDM) organisms, which are resistant to many standard treatments.

Why it matters

The rapid rise of drug-resistant bacteria in pediatric populations poses a critical challenge to public health and clinical treatment protocols.

✦Dive DeeperCreate a free account to unlock

Estimated national incidence of carbapenemase-producing carbapenem-resistant Enterobacterales (CP-CRE) among US children rose 92% from 2019 to 2024. New Delhi metallo-β-lactamase (NDM)–producing organisms drove the increase and overtook Klebsiella pneumoniae carbapenemase (KPC) as the leading carbapenemase.¹ The CDC-led analysis, published November 4, 2026, in the Journal of the Pediatric Infectious Diseases Society, drew on isolates submitted to the CDC Antimicrobial Resistance Laboratory Network (AR Lab Network).1

The findings extend a 2025 CDC analysis in Annals of Internal Medicine, which reported a more than 460% increase in NDM-CRE across all ages from 2019 to 2023.2,3 In the 2025 report, NDM-CRE incidence climbed from 0.25 to 1.35 per 100,000 population, outpacing every other carbapenemase type.2 Before the new analysis, the current epidemiology of CRE in US pediatric patients was poorly described, according to the authors.1

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
healthscience
✦

Get smarter about the news

Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.

Create free account

Already have an account? Sign in